Sarepta Therapeutics (SRPT) Given News Impact Rating of 0.25

Cornelia Mascio
Aprile 19, 2017

The count of Hold ratings in that period was 0.

PEDEVCO Corp. (:PED) shares typically trade an average volume of 198.61 and institutions hold 9.00% of the total shares.

Institutional investors have recently bought and sold shares of the company. First Allied Advisory Services Inc. boosted its stake in shares of Sarepta Therapeutics by 0.3% in the fourth quarter. BlackRock Fund Advisors increased its position in Sarepta Therapeutics by 7.2% in the third quarter. BlackRock Advisors LLC now owns 839,928 shares of the biotechnology company's stock valued at $51,580,000 after buying an additional 697,122 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Sarepta Therapeutics by 2.0% in the third quarter. Eagle Asset Management Inc. now owns 593,455 shares of the company's stock valued at $36,444,000 after buying an additional 239,165 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Sarepta Therapeutics by 2.7% in the third quarter. Jennison Associates LLC now owns 1,393,788 shares of the company's stock valued at $85,593,000 after buying an additional 647,030 shares during the period. Finally, BlackRock Group LTD raised its position in Sarepta Therapeutics by 433.6% in the third quarter. Bank of Montreal Can now owns 98,775 shares of the company's stock worth $2,924,000 after buying an additional 996 shares during the period.

The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) is a huge mover today! 371,319 shares of the company were exchanged. The stock's market capitalization is 1.69B. Sarepta Therapeutics has $108 highest and $4 lowest target.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Tuesday, February 28th. 1490159 shares were traded on Sarepta Therapeutics, Inc.'s last session. The firm earned $5.42 million during the quarter, compared to analysts' expectations of $4.86 million. The firm's quarterly revenue was up 333.6% compared to the same quarter a year ago. During the same quarter previous year, the firm posted ($1.44) earnings per share. (SRPT). The consensus rating is 1.9, indicating analysts in general look favorably on the company's future prospects. Wedbush maintained the stock with "Outperform" rating in Monday, October 10 report. Janney Montgomery Scott upgraded shares of Sarepta Therapeutics from a "neutral" rating to a "buy" rating and upped their price target for the company from $27.43 to $65.00 in a research report on Tuesday, January 3rd. Morgan Stanley cut their price target on shares of Sarepta Therapeutics from $53.00 to $33.00 and set a "weight" rating on the stock in a report on Wednesday, January 4th. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has "Outperform" rating given on Wednesday, April 6 by Oppenheimer. Finally, Vetr upgraded shares of Sarepta Therapeutics from a "buy" rating to a "strong-buy" rating and set a $34.53 target price for the company in a report on Monday, March 20th. One analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating to the company's stock. They now have a Dollars 45 price target on the stock. If you are reading this news story on another domain, it was illegally copied and reposted in violation of USA and global copyright & trademark legislation. If you are accessing this news story on another website, it was copied illegally and republished in violation of United States and global trademark and copyright legislation.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Firm focuses on the discovery and development of ribose nucleic acid -targeted therapeutics for the treatment of rare neuromuscular diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE